Combined Pharmacology of Ivabradine Hydrochloride & Atenolol useful in Chronic Stable Angina Pectoris

The main objective of this review article is to provide pharmacological information of combined therapy of Ivabradine Hydrochloride and Atenolol to researcher in development of combined dosage form for treatment of angina pectoris. It presents the pharmacology of combined Dose of drugs Ivabradine HCl and Atenolol which are treating Chronic Stable Angina Pectoris, Myocardial Infarction and Heart Failure. In modern clinical practice, many patients with stable angina pectoris require treatment with more than one anti-angina drug. In this combination of these 2 drugs show synergistic effect. The antianginal drug Ivabradine, specific If channel blocker responsible for depolarisation process and reduce myocardial oxygen consumption. Atenolol which is β1-blocker declines synthesis of cAMP (Cyclic adenosine monophosphate) which reduces BP (Blood Pressure) and delaying depolarisation process. According to clinical trials in 50mg Atenolol with 7.5 or 5mg Ivabradine taken in formulation, 4,954 patient of angina treated with for 4 months every day, from that 344 patient received treatment with Atenolol and other placebo only Ivabradine HCl. After 4 months that 344 patients show more beneficial effect than placebo and angina pectoris reduces from 2.8 ± 3.3 to 0.5 ± 1.3 bpm per week. So combination of both drugs show synergistic effect with no any unwanted causes or adverse drug effect.